Amanote Research
Register
Sign In
Single-Arm Phase II Trial Design Under Parametric Cure Models
Pharmaceutical Statistics
- United Kingdom
doi 10.1002/pst.1678
Full Text
Open PDF
Abstract
Available in
full text
Categories
Statistics
Probability
Pharmacology
Date
April 1, 2015
Authors
Jianrong Wu
Publisher
Wiley
Related search
Optimal Continuous-Monitoring Design of Single-Arm Phase II Trial Based on the Simulated Annealing Method
Contemporary Clinical Trials
Medicine
Pharmacology
Colorectal Liver Metastatic Disease: Efficacy of Irreversible Electroporation—a Single-Arm Phase II Clinical Trial (COLDFIRE-2 Trial)
BMC Cancer
Cancer Research
Oncology
Genetics
Meglumine Antimoniate Intralesional Infiltration for Localised Cutaneous Leishmaniasis: A Single Arm, Open Label, Phase II Clinical Trial
Memorias do Instituto Oswaldo Cruz
Medicine
Microbiology
A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma
Annals of Surgery
Surgery
Comparing How Single Arm Phase II Trial Data Can Support Approval of Oncologics by European Health Technology Assessment Bodies
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Adjuvant Rituximab, a Potential Treatment for the Young Patient With Graves Hyperthyroidism (RiGD): Study Protocol for a Single-Arm, Single-Stage, Phase II Trial
Yearbook of Paediatric Endocrinology
Mocetinostat for Relapsed Classical Hodgkin's Lymphoma: An Open-Label, Single-Arm, Phase 2 Trial
The Lancet Oncology
Oncology
Comparison of Error Rates in Single-Arm Versus Randomized Phase II Cancer Clinical Trials
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
OA10.05 an Open-Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients With Uncommon EGFR Mutation(KCSG-Lu15-09)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
